Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Plant-derived anti-inflammatory compounds show exciting potential, but a new review reveals why so few make it to the clinic. The core problem? Activity in a lab dish doesn't mean a compound actually hits its target at meaningful concentrations in the body. Researchers call for stricter evidence standards to separate real drug candidates from correlative findings.
A new review published in Immunity & Inflammation takes a hard look at why plant-derived anti-inflammatory compounds — despite their structural diversity and multi-target potential — rarely make it from the lab to the clinic. Led by Professor Weidong Zhang at Naval Medical University, the review lays out a rigorous framework for evaluating these compounds across chemical properties, target binding strength, dosing, and clinical maturity.
The authors zero in on two major bottlenecks: target engagement and dose. Many compounds show impressive activity in cell studies but reach undetectable levels in the bloodstream after oral dosing — meaning the mechanism observed in vitro may never play out in a real patient. The review also cautions against equating pathway inhibition with direct molecular targeting, a common overreach in natural product research.
Key Takeaways:
Why it matters: Chronic inflammation underlies autoimmune, metabolic, neurodegenerative, and cardiovascular diseases — conditions affecting hundreds of millions globally. Raising the evidentiary bar for plant-derived compounds could accelerate the development of safer, more affordable anti-inflammatory therapies.
